Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA H1047X Bortezomib + Temsirolimus + Topotecan small intestine adenocarcinoma predicted - resistant detail...
MLH1 mutant N/A small intestine adenocarcinoma not applicable detail...
MSH6 mutant N/A small intestine adenocarcinoma not applicable detail...
APC mutant N/A small intestine adenocarcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01202409 Phase II Panitumumab CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed USA 0
NCT01208103 Phase II Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed USA 0
NCT02034110 Phase II Dabrafenib + Trametinib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting USA | CAN 12
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting USA 0
NCT03000179 Phase II Avelumab Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma Active, not recruiting USA 0
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Recruiting USA 0
NCT03108131 Phase II Atezolizumab + Cobimetinib Cobimetinib and Atezolizumab in Advanced Rare Tumors Recruiting USA 0
NCT04491955 Phase II ALT-803 + CV301 + M7824 + NHS-IL12 ALT-803 + CV301 + M7824 Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers Recruiting USA 0
NCT04729322 Phase I Fecal microbiota + Nivolumab Fecal microbiota + Pembrolizumab Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders Not yet recruiting USA 0